Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsatuzumab in advanced non-squamous NSCLC
NCT01366131Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2011
- Primary completion
- Feb 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of parsatuzumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Genentech. Started Jun 2011; status: completed.
02
Drugs
parsatuzumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01366131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01366131.